Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 546

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Open access
Wang, Zi-Xian, Cui, Chengxu, Yao, Jun, Zhang, Yanqiao, Li, Mengxia, Feng, Jifeng, Yang, Shujun, Fan, Yun, Shi, Jianhua, Zhang, Xizhi, Shen, Lin, Shu, Yongqian, Wang, Cailian, Dai, Tianyang, Mao, Teng, Chen, Long, Guo, Zengqing, Liu, Bo, Pan, Hongming, Cang, Shundong, Jiang, Yi, Wang, Junye, Ye, Min, Chen, Zhendong, Jiang, Da, Lin, Qin, Ren, Wei, Wang, Junsheng, Wu, Lin, Xu, Yong, Miao, Zhanhui, Sun, Meili, Xie, Conghua, Liu, Ying, Wang, Qifeng, Zhao, Lina, Li, Qi, Huang, Canhong, Jiang, Ke, Yang, Kunyu, Li, Daojun, Liu, Yunpeng, Zhu, Zhitu, Chen, Rixin, Jia, Liqun, Li, Wei, Liao, Wangjun, Liu, Hong-Xu, Ma, Daiyuan, Ma, Jie, Qin, Yanru, Shi, Zhihong, Wei, Qichun, Xiao, Ke, Zhang, Yan, Zhang, Ying, Chen, Xin, Dai, Guanghai, He, Jianxing, Li, Junhe, Li, Guanghui, Liu, Yong, Liu, Zhihua, Yuan, Xianglin, Zhang, Junping, Fu, Zhichao, He, Yifu, Ju, Fang, Liu, Zheng, Tang, Peng, Wang, Tiejun, Wang, Weibo, Zhang, Jing, Luo, Xianming, Tang, Xiongwen, May, Rena, Feng, Hui, Yao, Sheng, Keegan, Patricia, Xu, Rui-Hua, Wang, Feng·2022·Cancer Cell
DOI 10.1016/j.ccell.2022.02.007
Open this paper in CoChat — free account

Abstract

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve advanced ESCC were randomized (1:1) to receive toripalimab or placebo in combination with paclitaxel plus cisplatin (TP) every 3 weeks for up to 6 cycles, followed by toripalimab or placebo maintenance. At the prespecified final analysis of progression-free survival (PFS), a significant improvement in PFS is observed for the toripalimab arm over the placebo arm (hazard ratio [HR] = 0.58; 95% CI, 0.46-0.74; p < 0.0001). The prespecified interim analysis of overall survival (OS) also reveals a significant OS improvement for patients treated with toripalimab plus TP over placebo plus TP (HR = 0.58; 95% CI, 0.43-0.78; p = 0.0004). The incidences of grade ≥3 treatment-emergent adverse events are similar between the two arms. Toripalimab plus TP significantly improves PFS and OS in patients with treatment-naïve, advanced ESCC, with a manageable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2022.02.007

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 546

Metadata

Authors
Wang, Z.-X., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., Yang, S., Fan, Y., Shi, J., Zhang, X., Shen, L., Shu, Y., Wang, C., Dai, T., Mao, T., Chen, L., Guo, Z., Liu, B., Pan, H., Cang, S., Jiang, Y., Wang, J., Ye, M., Chen, Z., Jiang, D., Lin, Q., Ren, W., Wang, J., Wu, L., Xu, Y., Miao, Z., Sun, M., Xie, C., Liu, Y., Wang, Q., Zhao, L., Li, Q., Huang, C., Jiang, K., Yang, K., Li, D., Liu, Y., Zhu, Z., Chen, R., Jia, L., Li, W., Liao, W., Liu, H.-X., Ma, D., Ma, J., Qin, Y., Shi, Z., Wei, Q., Xiao, K., Zhang, Y., Zhang, Y., Chen, X., Dai, G., He, J., Li, J., Li, G., Liu, Y., Liu, Z., Yuan, X., Zhang, J., Fu, Z., He, Y., Ju, F., Liu, Z., Tang, P., Wang, T., Wang, W., Zhang, J., Luo, X., Tang, X., May, R., Feng, H., Yao, S., Keegan, P., Xu, R.-H., & Wang, F.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-03
Volume
40
Issue
3
Pages
277-288.e3
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/j.ccell.2022.02.007
OpenAlex
W4214915284
Cited by
546
References
5
FWCI
97.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. https://app.cochat.ai/papers/10.1016/j.ccell.2022.02.007
The paper
Wang, Z.-X., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., Yang, S., Fan, Y., Shi, J., Zhang, X., Shen, L., Shu, Y., Wang, C., Dai, T., Mao, T., Chen, L., Guo, Z., Liu, B., Pan, H., . . . Wang, F. (2022). Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. https://doi.org/10.1016/j.ccell.2022.02.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.